Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

M G Bousser, P Amarenco, A Chamorro, M Fisher, I Ford, K Fox, M G Hennerici, H P Mattle, P M Rothwell, PERFORM Study Investigators, Martin Dennis

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study'. Together they form a unique fingerprint.

Medicine & Life Sciences